TSE:BLU

BELLUS Health Stock Forecast, Price & News

C$5.07

+0.27 (+5.63 %)

(As of 03/1/2021 12:00 AM ET)

Add

Compare

Today's Range

C$4.75

Now: C$5.07▼

C$5.15

50-Day Range

C$4.00

MA: C$4.78▼

C$5.74

52-Week Range

C$2.70

Now: C$5.07▼

C$16.68

Volume400,105 shs

Average Volume340,679 shs

Market CapitalizationC$397.17 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of chronic cough and other hypersensitization disorders. Its lead drug candidate includes BLU-5937, an oral small molecule antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of chronic cough and chronic pruritus. BELLUS Health Inc. was founded in 1993 and is headquartered in Laval, Canada.

Headlines

BELLUS Health Reports Year 2020 Financial Results and Business Highlights
February 25, 2021 | finance.yahoo.com

BELLUS Health shares are trading higher as traders circulate a TipRanks article mentioning the stock.
February 20, 2021 | benzinga.com

Will Bellus Health (BLU) Report Negative Q4 Earnings? What You Should Know
February 18, 2021 | msn.com

What Are Good Penny Stocks To Watch Before 2021? 3 Names To Know
December 7, 2020 | marketwatch.com

BELLUS Health to Participate in the Evercore ISI 3rd Annual Virtual HealthCONx Conference
November 24, 2020 | finance.yahoo.com

The President of BELLUS Health Inc. (TSE:BLU), Roberto Bellini, Just Bought 7.2% More Shares
October 23, 2020 | finance.yahoo.com

BELLUS Health prices $35M public offering in Canada and US
October 20, 2020 | seekingalpha.com

Is BELLUS Health Inc. (TSE:BLU) Popular Amongst Institutions?
September 7, 2020 | finance.yahoo.com

LD Micro 360 Companies Set to Present this Week
August 31, 2020 | finance.yahoo.com

BELLUS Health Reports Second Quarter 2020 Financial Results and Business Highlights
August 13, 2020 | finance.yahoo.com

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against BELLUS Health Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
July 9, 2020 | finance.yahoo.com

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Notifies BELLUS Health (BLU) Investors of Ongoing Investigation of Possible Securities Fraud, Encourages Investors and Persons Who May be Able to Assist Investigation to Contact the Firm
July 9, 2020 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange TSE

Industry Biotechnology

Sub-IndustryN/A

SectorMedical

Current SymbolTSE:BLU

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.bellushealth.com

Phone+1-450-6804500

Employees17

Year FoundedN/A

Debt

Debt-to-Equity Ratio0.46

Current Ratio11.64

Quick Ratio11.52

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesC$17,269.00

Price / Sales22,998.93

Cash FlowC$0.93 per share

Price / Cash Flow5.45

Book ValueC$1.92 per share

Price / Book2.64

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Outstanding Shares78,337,000

Market CapC$397.17 million

Next Earnings Date5/13/2021 (Estimated)

OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

0.48 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for BELLUS Health.

2.4 Community Rank

Outperform Votes
BELLUS Health has received 116 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
BELLUS Health has received 125 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
BELLUS Health has received 51.87% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about BELLUS Health and other stocks. Vote “Outperform” if you believe BLU will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BLU will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
BELLUS Health does not currently pay a dividend.
Dividend Growth
BELLUS Health does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, BELLUS Health insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of BELLUS Health is -8.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of BELLUS Health is -8.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
BELLUS Health has a P/B Ratio of 2.64. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

C$5.07

+0.27 (+5.63 %)

(As of 03/1/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive BLU News and Ratings via Email

Sign-up to receive the latest news and ratings for BLU and its competitors with MarketBeat's FREE daily newsletter.

BELLUS Health (TSE:BLU) Frequently Asked Questions

Is BELLUS Health a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for BELLUS Health in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BELLUS Health stock.
View analyst ratings for BELLUS Health or view top-rated stocks.

What stocks does MarketBeat like better than BELLUS Health?

Wall Street analysts have given BELLUS Health a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but BELLUS Health wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is BELLUS Health's next earnings date?

BELLUS Health is scheduled to release its next quarterly earnings announcement on Thursday, May 13th 2021.
View our earnings forecast for BELLUS Health.

How has BELLUS Health's stock been impacted by Coronavirus (COVID-19)?

BELLUS Health's stock was trading at C$13.01 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BLU stock has decreased by 61.0% and is now trading at C$5.07.
View which stocks have been most impacted by COVID-19.

Who are BELLUS Health's key executives?

BELLUS Health's management team includes the following people:

Mr. Roberto Francesco Bellini, Pres, CEO & Director (Age 41, Pay $661.99k)
Mr. FranÃ§ois Desjardins C.A., CPA, CPA, CA, VP of Fin. (Age 58, Pay $298.12k)
Dr. Denis Garceau, Sr. VP of Drug Devel. (Age 64, Pay $469.3k)
Dr. Catherine M. Bonuccelli, Chief Medical Officer (Age 63, Pay $473.7k)
Mr. Tony Matzouranis, VP of Bus. Devel. (Age 48, Pay $304.5k)
Mr. Ramzi Benamar, Chief Financial Officer (Age 48)
Mr. Daniel Matthews, Director of Investor Relations & Communications

Who are some of BELLUS Health's key competitors?

Some companies that are related to BELLUS Health include Trillium Therapeutics Inc. (TRIL.TO) (TRIL), iTeos Therapeutics (ITOS), Kinnate Biopharma (KNTE), Nurix Therapeutics (NRIX), Pharvaris (PHVS), Concordia International (CXR), PureTech Health (PRTC), 4D Molecular Therapeutics (FDMT), Pharming Group (PHAR), Sigilon Therapeutics (SGTX), Oxford Biomedica plc (OXB.L) (OXB), Landos Biopharma (LABP), Ergomed (ERGO), Inventiva (IVA) and Biotest Aktiengesellschaft (BIO).
View all of BLU's competitors.

What other stocks do shareholders of BELLUS Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BELLUS Health investors own include Exxon Mobil (XOM), Bombardier (BDRBF), AbbVie (ABBV), Energy Transfer (ET), General Electric (GE), The Coca-Cola (KO), Alexion Pharmaceuticals (ALXN), Advanced Micro Devices (AMD), The Boeing (BA) and The Walt Disney (DIS).

What is BELLUS Health's stock symbol?

BELLUS Health trades on the Toronto Stock Exchange (TSX) under the ticker symbol "BLU."

How do I buy shares of BELLUS Health?

Shares of BLU and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is BELLUS Health's stock price today?

One share of BLU stock can currently be purchased for approximately C$5.07.

How much money does BELLUS Health make?

BELLUS Health has a market capitalization of C$397.17 million and generates C$17,269.00 in revenue each year.

How many employees does BELLUS Health have?

BELLUS Health employs 17 workers across the globe.

What is BELLUS Health's official website?

The official website for BELLUS Health is www.bellushealth.com.

Where are BELLUS Health's headquarters?

BELLUS Health is headquartered at 9-275 Armand-Frappier Blvd, LAVAL, QC H7V 4A7, Canada.

How can I contact BELLUS Health?

BELLUS Health's mailing address is 9-275 Armand-Frappier Blvd, LAVAL, QC H7V 4A7, Canada. The company can be reached via phone at +1-450-6804500.

This page was last updated on 3/1/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here